Safety and tolerability of spesolimab in patients with ulcerative colitis.
Marc FerrantePeter M IrvingChristian Philipp SelingerGeert R A M D'HaensTanja KuehbacherUrsula E SeidlerSavion GropperThomas HaeufelSebastiano ForgiaSilvio DaneseJochen KlausBrian G FeaganPublished in: Expert opinion on drug safety (2022)
Spesolimab was generally well tolerated, with no unexpected safety concerns. The safety data are consistent with studies in other inflammatory diseases.